Establishment of Normal High Risk Breast Epithelial Cell Cultures, and A High Risk Cell Line and Tissue Repository From Breast Tissue From Women at High Risk of Breast Cancer
The NCI Surgery Branch
Multiple risk factors for breast cancer have been identified, including family history,
endocrine background, histologic changes in breast tissue, cancer in one breast, radiation
exposure, obesity, and others. The histologic phenotypes of breast carcinogenesis include a
spectrum of changes, beginning with normal appearing breast epithelium, progressing to
hyperplasia, atypical hyperplasia, in situ carcinoma, and finally invasive carcinoma.
Our present knowledge of high risk breast tissue is based on the study of a variety of
cellular sample types, which include fine needle aspirates, nipple aspirate fluid, core
needle biopsies, and breast tissue from mastectomy or segmentectomy specimens.
Valid preclinical models are needed which utilize homogenous human cellular material which
can be studied over time in large quantities.
A model which may be ideally suited to the metabolic and molecular studies of breast
epithelial cells is an in vitro cell line model developed from high risk breast tissue.
In this study normal breast tissue will be acquired from each of the high risk sites for
breast cancer in the breast. These tissues will be used to develop breast epithelial cell
lines for in vitro studies, and to establish a high risk cell line and tissue repository.
To acquire normal breast tissue from each of the high risk sites for breast cancer in the
To develop breast epithelial cell lines from the normal high risk breast tissue from each of
the major high risk sites.
To establish a repository of high risk breast epithelial cell lines and high risk normal
breast tissue which can be used as a resource for pilot studies at NIH and other
participating centers to characterize high risk breast epithelial cells
Women age 20 - 80 years who have an increased risk of breast cancer because they are members
of a high risk breast or ovarian cancer family.
Women with a history of ipselateral breast cancer, either invasive or in situ, and a normal
contralateral breast by mammography (within the past 12 months) and a normal physical
examination of the contralateral breast and adjacent lymph node bearing areas, or be
undergoing prophylactic mastectomy.
Women without breast cancer but with a Gail model estimate of 5-year risk of breast cancer
of 1.67 percent or higher.
Women with bilateral breast cancer (invasive or in situ) who have not received whole breast
irradiation to both breasts.
Women with a previous history of mediastinal irradiation for lymphoma before the age of 30
and who are now greater than 5 years since completing radiation therapy.
Normal women not at increased risk of breast cancer (Gail model Index of less than 1.50
percent) and without abnormal findings in the breast by physical examination and mammography
to serve as normal control tissue.
Women with a mutation in a breast cancer susceptibility gene, but whose family history is
Absence of significant cardiac, hepatic or renal disease, which, in the opinion of the PI,
is likely to cause metabolic changes in the breast tissue.
A tissue acquisition in which Normal breast tissue will be collected from women at high risk
of breast cancer at NIH and at other institutions as well. Centers collecting tissue for
this protocol must have IRB approval for this study and an IRB approved Informed Consent.
All breast tissue will be obtained from surgical specimens acquired as part of planned
surgical procedures. Short-term cell lines will be developed from this tissue and confirmed
cytologically and by expression of cytokeratins. Multiple cell lines from each of the high
risk categories will be developed.
These cell lines and the respective tissues will be used to establish a repository of high
risk breast epithelial cell lines and high risk breast tissues which can be used to further
define the carinogenic pathway for breast cancer. Early passages of these cell cultures and
the respective normal breast tissue will be stored for future studies.
100 patients will be enrolled over a period of 5 years.
David N Danforth, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|
|Walter Reed Army Medical Center||Washington, District of Columbia 20307-5000|